Carl Regillo, MD, explains why wet AMD anti‑VEGF results lag in real life and how newer agents extend dosing, yet the burden persists.
Age-Related Macular Degeneration
Advertisement
Advertisement
Trending on AJMC
1
Ocrelizumab Led to Declines in Immunoglobulins in Patients With MS
2
House Panel Advances Bills to Expand Veterans’ Health Care Access
3
Orca-T Gains FDA Approval for Matched Donor Stem Cell Transplant
4
House Passes Bill to Ease Medicare ACO Digital Quality Reporting Burden
5